Non-Invasive Liver Fibrosis Markers Decrease During Weight Loss in Individuals with Obesity, Non-Alcoholic Fatty Liver Disease, and the Metabolic Syndrome

<jats:p>Liver fibrosis is a serious complication of non-alcoholic fatty liver disease (NAFLD) and the metabolic syndrome (MetS), conditions closely linked to obesity. We investigated the levels and dynamics of liver fibrosis biomarkers and liver fat content during personalized weight loss intervention in individuals with obesity, NAFLD, and concomitant MetS (n=30), with assessments at baseline, 1, and 5 months. Liver fat content decreased significantly (p &amp;lt; 0.0001), corresponding with complete resolution of steatosis in 36.7% of the participants, after 1 month of weight loss. Similarily, the fibrosis markers: T1 (p &amp;lt; 0.01), CK18 (p &amp;lt; 0.01), PIIINP (p &amp;lt; 0.0001), TIMP1 (p &amp;lt; 0.001), and MACK3 (p &amp;lt; 0.001) dropped after 1 month. CK18 (p &amp;lt; 0.01) and MACK3 (p &amp;lt; 0.001) further changed from 1 to 5 months, while FNI decreased after 5 months (p &amp;lt; 0.01). Except for CK18, the dynamics of these changes were more pronounced from baseline to 1 month compared with 1 to 5 months. Finally, MACK3 showed promise for explaining T1.Our study underlines the importance of weight loss in swiftly mitigating liver steatosis and supports the integration of non-invasive biomarkers to monitor fibrosis risk in individuals with obesity, NAFLD, and MetS.</jats:p>